A Phase I Dose Escalation Trial of Once Daily Oral Treatment BIBW 2992 Plus Gemcitabine or Docetaxel in Patients With Relapsed or Refractory Solid Tumors

Trial Profile

A Phase I Dose Escalation Trial of Once Daily Oral Treatment BIBW 2992 Plus Gemcitabine or Docetaxel in Patients With Relapsed or Refractory Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Jun 2016

At a glance

  • Drugs Afatinib (Primary) ; Docetaxel; Gemcitabine
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 11 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 02 Apr 2015 Planned End Date changed from 1 Mar 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov record.
    • 02 Apr 2015 Planned primary completion date changed from 1 Mar 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top